C-terminal modifications regulate MDM2 dissociation and nuclear export of p53

Nature Cell Biology

Volumn 9, Issue 4, 2007, Pages 428-435

  Carter, Stephanie ^a   Bischof, Oliver ^b   Dejean, Anne ^b   Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PROTEASOME; PROTEIN MDM2; PROTEIN P53; SUMO PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DISSOCIATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REGULATORY MECHANISM; SUMOYLATION; TUMOR CELL; UBIQUITINATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 34047103990     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1562     Document Type: Article

References (35)

1. Vousden, K. H. Activation of the p53 tumor suppressor gene. Biochem. Biophys. Acta 1602, 47-59 (2002).
2. Li, M. et al. Mono- versus polyubiquitination: Differential control of p53 fate by Mdm2. Science 302, 1972-1975 (2003).
3. Qian, S. B., Ott, D. E., Schubert, U., Bennink, J. R. & Yewdell, J. W. Fusion proteins with COOH-terminal ubiquitin are stable and maintain dual functionality in vivo. J. Biol. Chem. 277, 38818-38826 (2002).
4. Zhang, Y. & Xiong, Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 292, 1910-1915 (2001).
5. Stommel, J. M. et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18, 1660-1672 (1999).
6. Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A. & Rotter, V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10, 6565-6577 (1990).
7. Xirodimas, D. P., Saville, M. K., Bourdon, J. C., Hay, R. T. & Lane, D. P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118, 83-97 (2004).
8. Whitby, F. G., Xia, G., Pickart, C. M. & Hill, C. P. Crystal structure of the human ubiquitin-like protein NEDD8 and interactions with ubiquitin pathway enzymes. J. Biol. Chem. 273, 34983-34991 (1998).
9. Shih, S. C., Sloper-Mould, K. E. & Hicke, L. Monoubiquitin carries a novel internalization signal that is appended to activated receptors. EMBO J. 19, 187-198 (2000).
10. Lee, J. C., Wang, G. X., Schickling, O. & Peter, M. E. Fusing DEDD with ubiquitin changes its intracellular localization and apoptotic potential. Apoptosis 10, 1483-1495 (2005).
11. Hoeller, D. et al. Regultion of ubiquitin-binding proteins by monoubiquitination. Nature. Cell. Biol. 8, 163-169 (2006).
12. Lohrum, M. A. E., Woods, D. B., Ludwig, R. L., Bálint, E. & Vousden, K. H. C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell. Biol. 21, 8521-8532 (2001).
13. Gu, J., Nie, N., Wiederschain, D. & Yuan, Z.-M. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol. Cell. Biol. 21, 8533-8546 (2001).
14. Milner, J., Medcalf, E. A. & Cook, A. C. Tumor suppressor p53: Analysis of wild-type and mutant p53 Complexes. Mol. Cell. Biol. 11, 12-19 (1991).
15. Zerrahn, J. et al. Corelation between conformational phenotype of p53 and its subcellular location. Oncogene 7, 1371-1381 (1992).
16. Pickart, C. M. Mechanisms underlying ubiquitination. Annual Rev. Biochem. 70, 503-533 (2001).
17. Rodriguez, M. S. et al. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18, 6455-6461 (1999).
18. Rodriguez, M. S., Dargemont, C. & Hay, R. T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276, 12654-12659 (2001).
19. Hicke, L., Schubert, H. L. & Hill, C. P. Ubiquitin-binding domains. Nature Rev. Mol. Cell Biol. 6, 610-621 (2005).
20. Kahyo, T., Nishida, T. & Yasuda, H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell 8, 713-718 (2001).
21. Schmidt, D. & Muller, S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc. Natl Acad. Sci USA 99, 2872-2877 (2002).
22. Bischof, O. et al. The E3 SUMO ligase PIASy is a novel regulator of cellular senscence and apoptosis. Mol. Cell. 22, 783-794 (2006).
23. Nelson, V., Davis, G. E. & Maxwell, S. A. A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis. Apoptosis 6, 221-234 (2001).
24. Kulikov, R., Winter, M. & Blattner, C. Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J. Biol. Chem. 281, 28575-28583 (2006).
25. Boyd, S. D., Tsai, K. Y. & Jacks, T. An Intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nature Cell Biol. 2, 563-568 (2000).
26. Geyer, R. K., Yu, Z. K. & Maki, C. G. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nature Cell Biol. 2, 569-573 (2000).
27. Marston, N. J., Jenkins, J. R. & Vousden, K. H. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10, 1709-1715 (1995).
28. Kawaguchi, Y., Ito, A., Appella, E. & Yao, T. P. Charge modification at multiple C-termlnal lysine residues regulates p53 oligomerization and its nucleus-cytoplasm trafficking. J. Biol. Chem. 281, 1394-1400 (2006).
29. Feng, L., Lin, T., Uranishi, H., Gu, W. & Xu, Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 25, 5389-5395 (2005).
30. Krummel, K. A., Lee, C. J., Toledo, F. & Wahl, G. M. The C-terminal lysines fine-tune p53 stress response in a mouse model but are not required for stability control or transactivation. Proc. Natl Acad. Sci. USA 102, 10188-10193 (2005).
31. Vousden, K. H. p53 and PUMA: A deadly duo. Science 9, 1685-1686 (2005).
32. Uchida, C. et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 24, 160-169 (2005).
33. Ashcroft, M., Woods, D. B., Copeland, T. D. & Vousden, K. H. Phosphorylation of HDM2 by Akt. Oncogene 21, 1955-1962 (2002).
34. Desterro, J. M., Rodriguez, M. S. & Hay, R. T. SUMO-1 modification of IkBα inhibits NF-κB activation. Mol. Cell 2, 233-239 (1998).
35. Marston, N. J., Crook, T. & Vousden, K. H. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9, 2707-2716 (1994).